Hemoglobinopathies: Structural Hb Variants, Thalassemias, and HPFH

Hemoglobinopathies

Introduction to Hemoglobinopathies

Hemoglobinopathies are a group of inherited blood disorders caused by abnormalities in the structure or production of hemoglobin (Hb). These disorders are significant in medical genetics due to their global prevalence and impact on health.

• Structural Variants: Mutations that alter the amino acid sequence of the globin chains without affecting the rate of synthesis. Typically, these are single base changes.

• Thalassemias: Disorders resulting from decreased synthesis of one or more globin chains, leading to an imbalance in the relative amounts of α and β chains.

• Hereditary Persistence of Fetal Hemoglobin (HPFH): A condition where fetal hemoglobin (HbF) continues to be produced into adulthood due to genetic mutations.

Structural Hemoglobin Variants

Common Hemoglobin Mutations

Structural variants of hemoglobin arise from point mutations in the globin genes, leading to amino acid substitutions that can affect hemoglobin function and stability.

Hemoglobin	Point Mutation Position	Amino Acid Substitution	Codon and Base Substitution
HbS	Beta 6	Glu → Val	GAG → GTG
HbC	Beta 6	Glu → Lys	GAG → AAG
HbE	Beta 26	Glu → Lys	GAG → AAG
HbD	Beta 121	Glu → Gln	GAG → CAG

Hemoglobin S (HbS) and Hemoglobin C (HbC)

• HbS: Causes sickle cell disease due to decreased solubility and sickling of red blood cells.

• HbC: Mutation at beta chain position 6 (Glu → Lys). Does not cause sickling but leads to mild hemolytic anemia. Common in West Africa and the Middle East.

• Hemoglobin C Disease: Homozygous individuals (HbCC) have mild anemia and splenomegaly. Heterozygotes are usually asymptomatic.

Hemoglobin E (HbE)

• HbE: Most common structurally abnormal hemoglobin. Prevalent in Southeast Asia.

• Mutation at beta chain position 26 (Glu → Lys, E26K).

• Affects splicing of beta globin RNA, leading to reduced synthesis of normal beta globin.

• Homozygotes are asymptomatic or have mild anemia; heterozygotes are asymptomatic.

• Genetic compounds of HbE with other thalassemia alleles can result in variable phenotypes.

Example: In the homozygous state (HbEE), mild anemia and microcytosis are seen. The carrier state is asymptomatic.

Hemoglobin SC Disease

• Compound heterozygote: one β-globin allele has HbS mutation, the other has HbC mutation.

• Hb levels near low normal values.

• No symptoms unless a medical problem arises.

Clinical Manifestations of Hemoglobin Mutants

Type	Example	Clinical Manifestations
Sickling	HbS	Sickling due to decreased solubility
Unstable	Hb Bristol	Anemia
Abnormal Oxygen Affinity	Hb Kansas, Hb Chesapeake	Mild anemia, polycythemia due to decreased O2 transport
M Hemoglobin	HbM Boston	Cyanosis due to ferric hemoglobin
Decreased Synthesis	Hb Lepore	Thalassemia

Thalassemias

Overview of Thalassemias

Thalassemias are inherited disorders caused by mutations that reduce the synthesis of either the α or β globin chains. This leads to an imbalance in the α:β chain ratio, which underlies the clinical symptoms.

• α-Thalassemia: Reduced or absent α-chain synthesis, resulting in an excess of β-chains. Common mutations: deletions.

• β-Thalassemia: Impaired β-chain synthesis, resulting in an excess of α-chains. Common mutations: point mutations.

Example: Deletion of one or more α-globin genes leads to α-thalassemia trait or disease, while point mutations in the β-globin gene cause β-thalassemia.

Genetics and Inheritance

• Both α- and β-thalassemias are inherited in an autosomal recessive manner.

• Clinical severity depends on the number and type of mutated or deleted globin genes.

Global Distribution

Hemoglobinopathies and thalassemias are most prevalent in regions such as Africa, the Middle East, South Asia, and Southeast Asia. It is estimated that 270 million carriers of mutant globin genes exist worldwide, with 300,000–400,000 severely affected infants born annually, mostly in Asia, India, and the Middle East.

Hereditary Persistence of Fetal Hemoglobin (HPFH)

HPFH Overview

HPFH is a benign genetic condition in which the production of fetal hemoglobin (HbF) continues into adulthood. This can ameliorate symptoms in individuals with other hemoglobinopathies, such as sickle cell disease or β-thalassemia.

• Cause: Mutations in the regulatory regions of the β-globin gene cluster.

• Clinical significance: Increased HbF levels can reduce the severity of symptoms in other hemoglobinopathies.

Hemoglobin E Mutation: Molecular Details

Mutation Mechanism

The HbE mutation is a G to A transition at codon 26 (GAG to AAG) in exon 1 of the β-globin gene, resulting in a glutamic acid to lysine substitution (E26K). This mutation also activates a cryptic splice site at codon 25, leading to reduced levels of correctly spliced β-globin mRNA.

• Exon 1 mutation: $\text{GAG} \rightarrow \text{AAG}$ at codon 26

• Splice site activation: Cryptic donor site at codon 25 (GUG/GUAG)

• Result: Reduced synthesis of normal β-globin, leading to mild anemia

Example: Individuals with HbE mutation may be asymptomatic or have mild anemia, but compound heterozygotes with β-thalassemia alleles can have more severe disease.

Summary: Hemoglobinopathies as a Global Health Burden

Hemoglobinopathies, including structural variants and thalassemias, represent a major global health challenge due to their high prevalence and potential for severe disease. Understanding the genetics, molecular mechanisms, and clinical manifestations is essential for diagnosis, management, and genetic counseling.

Additional info: The notes have been expanded to provide definitions, examples, and context for key terms and concepts relevant to a college genetics course.